Peschel G, Weigand K, Grimm J, Müller M, Buechler C. Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C. World J Hepatol 2023; 15(12): 1315-1324 [PMID: 38223417 DOI: 10.4254/wjh.v15.i12.1315]
Corresponding Author of This Article
Christa Buechler, PhD, Senior Researcher, Department of Internal Medicine I, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg 93053, Germany. christa.buechler@klinik.uni-regensburg.de
Research Domain of This Article
Virology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Dec 27, 2023; 15(12): 1315-1324 Published online Dec 27, 2023. doi: 10.4254/wjh.v15.i12.1315
Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C
Georg Peschel, Kilian Weigand, Jonathan Grimm, Martina Müller, Christa Buechler
Georg Peschel, Kilian Weigand, Jonathan Grimm, Martina Müller, Christa Buechler, Department of Internal Medicine I, University Hospital Regensburg, Regensburg 93053, Germany
Georg Peschel, Department of Internal Medicine, Klinikum Fürstenfeldbruck, Fürstenfeldbruck 82256, Germany
Kilian Weigand, Department of Gastroenterology, Gemeinschaftsklinikum Mittelrhein, Koblenz 56073, Germany
Author contributions: Peschel G, Weigand K and Buechler C were the guarantors and designed the study; Peschel G, Weigand K and Grimm J participated in the acquisition of the serum samples; Buechler C participated in the analysis, and interpretation of the data, and drafted the initial manuscript; Peschel G, Weigand K, Grimm J, Müller M and Buechler C revised the article critically for important intellectual content.
Institutional review board statement: The study protocol was approved by the ethical committee of the University Hospital of Regensburg (14-101-0049, date of approval: May 22, 2014).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Christa Buechler, PhD, Senior Researcher, Department of Internal Medicine I, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, Regensburg 93053, Germany. christa.buechler@klinik.uni-regensburg.de
Received: September 20, 2023 Peer-review started: September 20, 2023 First decision: October 25, 2023 Revised: November 3, 2023 Accepted: November 21, 2023 Article in press: November 21, 2023 Published online: December 27, 2023 Processing time: 95 Days and 20 Hours
Core Tip
Core Tip: Omentin-1 is an adipokine well described for its anti-inflammatory and insulin-sensitizing functions. Aim of this study was to identify the effect of hepatitis C virus (HCV) infection and liver cirrhosis on serum omentin-1 levels. This study showed that circulating omentin-1 levels of HCV infected patients and non-infected healthy controls were similar. Accordingly, serum omentin-1 levels did not change upon effective elimination of the virus by direct acting antiviral therapy. Serum omentin-1 was not associated with diabetes or C-reactive protein in the HCV cohort. Patients with liver cirrhosis had increased serum omentin-1 levels before treatment and at sustained virological response 12 in comparison to HCV patients without liver cirrhosis. This analysis shows that increased serum omentin-1 levels of chronic HCV patients with liver cirrhosis persist after viral elimination. Serum omentin-1 has no role in the favourable metabolic outcomes of HCV eradication.
